Longitudinal CSF Biomarkers in Patients with Early Parkinson Disease and Healthy Controls  

Oleh:

Mollenhauer, Brit ; Caspell-Garcia, Chelsea J. ; Coffey, Christopher S. ; Taylor, Peggy ; Shaw, Leslie M. ; Trojanowski, John Q. ; Singleton, Andy ; Frasier, Mark ; Marek, Kenneth ; Galasko, Douglas

Jenis: Article from Journal - ilmiah internasional
Dalam koleksi: Neurology (Official Journal of The American Academy of Neurology) vol. 89 no. 19 (Nov. 2017), page 1959-1969.
Topik: Cohort Studies; Outcome Research; Parkinson Disease
Fulltext: N11 v89 n19 p1959 kelik2017.pdf (182.77KB)

Ketersediaan

Perpustakaan FK Nomor Panggil: N11.K Non-tandon: 1 (dapat dipinjam: 0) Tandon: tidak ada

Lihat Detail Induk

Isi artikel

Objective: To analyze longitudinal levels of CSF biomarkers in drug-naive patients with Parkinson disease (PD) and healthy controls (HC), examine the extent to which these biomarker changes relate to clinical measures of PD, and identify what may influence them. Methods: CSF a-synuclein (a-syn), total and phosphorylated tau (t- and p-tau), and ß-amyloid 1–42 (Aß42) were measured at baseline and 6 and 12 months in 173 patients with PD and 112 matched HC in the international multicenter Parkinson's Progression Marker Initiative. Baseline clinical and demographic variables, PD medications, neuroimaging, and genetic variables were evaluated as potential predictors of CSF biomarker changes. Results: CSF biomarkers were stable over 6 and 12 months, and there was a small but significant increase in CSF Aß42 in both patients with patients with PD and HC from baseline to 12 months. The t-tau remained stable. The p-tau increased marginally more in patients with PD than in HC. a-syn remained relatively stable in patients with PD and HC. Ratios of p-tau/t-tau increased, while t-tau/Aß42 decreased over 12 months in patients with PD. CSF biomarker changes did not correlate with changes in Movement Disorder Society–sponsored revision of the Unified Parkinson’s Disease Rating Scale motor scores or dopamine imaging. CSF a-syn levels at 12 months were lower in patients with PD treated with dopamine replacement therapy, especially dopamine agonists. Conclusions: These core CSF biomarkers remained stable over 6 and 12 months in patients with early PD and HC. PD medication use may influence CSF a-syn. Novel biomarkers are needed to better profile progressive neurodegeneration in PD.

Opini Anda

Klik untuk menuliskan opini Anda tentang koleksi ini!

Kembali